Beschreibung
PET/CT has higher sensitivity, specificity and accuracy in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with MBC and monitoring the therapy response in relation to different molecular sub-types. Material and Methods: 40 patients classified into 4 molecular sub-types; Luminal A like 13 patients, Luminal B+ sub type 15 patients, Luminal B- sub type 4 patients and Basal like sub type 8 patients. All patients performed PET-CT before treatment, while 34 patients perform PET-CT at end of therapy. Results: on lesion based analysis 120 metastatic lesions are seen in CT and bone scan and 76 lesions are seen in PET/CT. During follow up, the majority of luminal A group showed complete response to therapy luminal B+ subgroup showed partial response and most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular sub-types. The mean SUV max showed relation to the different molecular sub-types.
Autorenporträt
H. Moustafa: Doctorate degree, 11/1979, Professor of Nuclear Medicine, Cairo University (28/2/1990 - till now), Head of AFRA Nuclear Medicine project in Egypt (2003-2030), Head of Egyptian Society of Nuclear Medicine Specialists 2008 - till now, Head of Egyptian journal of nuclear medicine.
